FOR HEALTHCARE PROFESSIONALS ONLY

This website is a global information resource. It is intended for healthcare professionals only outside of the United States of America (US) who are interested in information on Foundation Medicine®. This site is not intended to provide medical advice and/or treatment guidance. If you are a US healthcare professional click here.

This site is produced by Roche as a partner of Roche Foundation Medicine.

You are now leaving the Roche Foundation Medicine website. Links to all external sites are provided as a resource to our visitors. Hoffmann-La Roche Inc. ("Roche") accepts no responsibility for the content of these sites. Roche does not control these sites, and the opinions, claims, or comments expressed on these sites should not be attributed to Roche, except where indicated. We recommend that you consult with your local Roche representative to obtain more information about any Roche product or service.

Alt

Order now

Ordering process

A simple, convenient ordering process

Ordering a Foundation Medicine service is a simple, convenient process and our turnaround times (time from receipt of sample at our laboratory to receiving Foundation Medicine report: less than 2 weeks for FoundationOne Liquid CDx, 14 days for FoundationOne CDx, 21 days for FoundationOne Heme) are comparable to less comprehensive tests.1–3

Ordering a Foundation Medicine service

1 Order test 2 Prepare sample 3 Send the sample to Foundation Medicine 4 Analysis of the sample and evaluationof the results 5 Receive patient report

Specimen instructions

Formalin-fixed paraffin-embedded (FFPE) specimens, including cut slide specimens, are acceptable4

Two 8.5 mL peripheral
blood specimens5
 

Peripheral blood, bone marrow aspirate or FFPE tissue specimens may be used with ≥20% tumour cell content6
PD-L1 supplementary test

PD-L1 by IHC can be ordered as a supplemental test

PD-L1 expression (based on IHC) does not correlate with Tumour Mutational Burden (TMB). Therefore, PD-L1 testing and TMB status could complement each other for guiding cancer immunotherapy treatment.7–9 PD-L1 by IHC can be ordered as a supplemental test.
Customer support

Customer support to facilitate patient care

We provide customer support built on an extraordinary wealth of knowledge, expertise and dedication to help you provide the best possible care.
Expert pathology review of sample analysis Specialist bioinformatics team identifies clinically relevant mutations Oncologists and genomics experts curate reports based on latest literature Customer support team the process Medical team is available to support you with interpretation of the report on request

IHC, immunohistochemistry; PD-L1, programmed death-ligand 1; TMB, Tumour Mutational Burden.

M-IE-00000628
References
  1. FoundationOne®CDx Technical Specifications, 2018. Available at: www.rochefoundationmedicine.com/f1cdxtech (Accessed August 2020).
  2. Data on file: FoundationOne Liquid CDx Technical Specifications, 2020. Available at: http://www.eifu.online/FMI/190070862 (Accessed August 2020).
  3. FoundationOne®Heme Technical Specifications, 2017. Available at: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed August 2020).
  4. FoundationOne®CDx Specimen Instructions, 2018. Available at: www.rochefoundationmedicine.com/specimen (Accessed August 2020).
  5. Data on file: FoundationOne Liquid CDx Specimen Instructions.
  6. FoundationOne®Heme Specimen Instructions, 2017. Available at: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed August 2020).
  7. Kamzi S. Presented at ESMO Immuno Oncology Congress 2017; Geneva, Switzerland: Poster no. 35P.
  8. Rizvi H et al. J Clin Oncol 2018; 36: 633–641.
  9. Hellmann MD et al. Cancer Cell 2018; 33: 843–852.e4.